Recombinant Human DEFB130 Protein，His

DEFB130, a member of the defensin protein family, plays a crucial role in the innate immune response. Defensins are small cationic peptides that exhibit antimicrobial activity against a broad range of pathogens, including bacteria, fungi, and viruses. DEFB130 is primarily expressed in human epithelial tissues, particularly in the skin and respiratory tract, where it serves as a first line of defense against microbial invasion. Research into DEFB130 has gained traction due to its potential therapeutic applications in treating infections and inflammatory diseases. The recombinant expression of DEFB130 has enabled scientists to study its structural features and functional mechanisms more effectively. By producing this protein in a laboratory setting, researchers can investigate its antimicrobial properties, binding interactions with pathogens, and immunomodulatory effects. Furthermore, understanding the genetic regulation of DEFB130 expression may uncover insights into how variations in this defensin contribute to individual susceptibility to infections and inflammation. The study of DEFB130 also holds promise for the development of novel antimicrobial agents and therapeutic strategies that harness the body’s natural defenses. Given the rising prevalence of antibiotic resistance, DEFB130 and other defensins represent a vital area of research aimed at alternative treatment options that can mitigate infectious diseases while promoting human health.